tbuckley/cabot-search huggingface dataset:
“Horrific” treatment of children with learning disabilities must be ended, say MPs and peers
Authors: Adrian O’Dowd
Journal: BMJ (2019)

Treatment of young people with learning disabilities or autism in mental health hospitals is so bad that their human rights are being breached, claim MPs and peers.

A highly critical inquiry report by the parliamentary Joint Committee on Human Rights published on 1 November condemned the “horrific reality” of the conditions under which many young people were detained in mental health hospitals.1

Evidence to the inquiry had been so “stark” and consistent that the committee said it had lost confidence that the system was doing what it claimed to and feared that the regulator the Care Quality Commission …
Treatment Outcomes of Early-Stage Natural-Killer/T-Cell Lymphomas Treated with Chemoradiotherapy: Data from 3 Tertiary Cancer Centres in Singapore
Authors: Ya Hwee Tan, Siqin Zhou, Liu Xin, Soon Thye Lim, Miriam Tao, Daryl Tan, Michelle Poon, Mohamad Farid, Colin Phipps Diong, Yuh Shan Lee, Shin-Yeu Ong, Nicholas Francis Grigoropoulos, Kheng Wei Yeoh, Nagavalli Somasundaram, Eileen Yi Ling Poon, Jason Yongsheng Chan, Esther Wei Yin Chang, Tiffany Tang
Journal: Blood (2019)
Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
Authors: Ali Bukhari, Vivek Kesari, Reza Sirous, Noa G. Holtzman, Seung Tae Lee, Natalie Gahres, Elizabeth Hutnick, Kathleen Ruehle, Mehmet Hakan Kocoglu, Ashraf Z. Badros, Jean A. Yared, Nancy M. Hardy, Aaron P. Rapoport, Babak Saboury, Saurabh Dahiya
Journal: Blood (2019)
Targeting Aurora Kinase B with AZD2811 Enhances Venetoclax Activity in TP53-Mutant AML
Authors: Fiona C Brown, Jelena Urosevic, Urszula Polanska, Jan Cosaert, J. Elizabeth Pease, Giovanna Pomilio, Veronique Litalien, Jon Travers, Andrew H. Wei
Journal: Blood (2019)
DDIS-29. BRAIN-PENETRANT MICROTUBULE-TARGETING AGENT, ST-401, KILLS GLIOBLASTOMA THROUGH A NOVEL MECHANISM
Authors: Eric Horne, Cong Xu, Juan-Jesus Vicente, P J Cimino, Michael Wagenbach, Ernest Hamel, Rick Gussio, Philippe Diaz, Benjamin Uhlenbruck, Thomas Deckwerth, Linda Wordeman, Eric Holland, Nephi Stella
Journal: Neuro-Oncology (2019)

Abstract Glioblastomas are particularly sensitive to mitotic disruption when compared with nonmalignant cells and thus microtubule-targeting agents (MTA) represent promising therapeutics to treat patients with glioblastomas; but few such compounds pass the blood brain barrier. We developed a series of modified carbazoles, evaluated their anti-cancer activity in glioblastoma cells in culture and identified ST-401 as the most potent compound (IC50, 10 – 102 nM, depending on the cell line). Testing of ST-401 on the NCI 60 cancer cell panel indicated that its anti-tumor activity does not correlate with any of the compounds tested thus far through this platform but showed weak correlations for taxol (p=0.46) and vinblastine (p=0.34). Thus, ST-401 may kill cancer cells through a novel mechanism related to disruption of MT function. Biochemical analysis indicates that ST-401 binds to the colchicine site of tubulin and inhibits tubulin assembly. Real-time imaging of MT dynamics in cells in culture shows that ST-401 reduces MT assembly rates but in a reversible fashion. ST-401 potently blocks mitotic progression and triggers cell death in multiple glioblastoma lines in culture, including patient-derived glioblastomas of the proneural, mesenchymal and classical subtypes. We established the maximum tolerated dose (MTD) of ST-401 in mice (20 mg/kg/bdip) and found that its acute i.p. injection results in micromolar amounts of ST-401 in mouse brain. Using this treatment regimen, we found that ST-401 reduces tumor growth and doubles overall survival in a human tumor xenograft mouse model system. ST-401 also increases by 2-fold overall survival in the genetic RCAS-PDGF glioblastomas mouse model treated with standard care (radiation and Temodar® treatments). Histological analysis of RCAS-PDGF glioblastoma tissue shows that ST-401 triggers mitotic arrest of glioblastoma cells. ST-401 represents a promising lead compound for the treatments for patients diagnosed with glioblastomas.
Ending Congenital Syphilis
Authors: Irene A. Stafford, Pablo J. Sánchez, Barbara J. Stoll
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Contribution of Geographic Location to Disparities in Ovarian Cancer Treatment
Authors: Carolina Villanueva, Jenny Chang, Scott M. Bartell, Argyrios Ziogas, Robert Bristow, Verónica M. Vieira
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: More than 14,000 women in the United States die of ovarian cancer (OC) every year. Disparities in survival have been observed by race and socioeconomic status (SES), and vary spatially even after adjusting for treatment received. This study aimed to determine the impact of geographic location on receiving treatment adherent to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for OC, independent of other predictors. Patients and Methods: Women diagnosed with all stages of epithelial OC (1996–2014) were identified through the California Cancer Registry. Generalized additive models, smoothing for residential location, were used to calculate adjusted odds ratios (ORs) and 95% CIs for receiving nonadherent care throughout California. We assessed the impact of distance traveled for care, distance to closest high-quality hospital, race/ethnicity, and SES on receipt of quality care, adjusting for demographic and cancer characteristics and stratifying by disease stage. Results: Of 29,844 patients with OC, 11,419 (38.3%) received guideline-adherent care. ORs for nonadherent care were lower in northern California and higher in Kern and Los Angeles counties. Magnitudes of associations with location varied by stage (OR range, 0.45–2.19). Living farther from a high-quality hospital increased the odds of receiving nonadherent care (OR, 1.18; 95% CI, 1.07–1.29), but travel &gt;32 km to receive care was associated with decreased odds (OR, 0.76; 95% CI, 0.70–0.84). American Indian/other women were more likely to travel greater distances to receive care. Women in the highest SES quintile, those with Medicare insurance, and women of non-Hispanic black race were less likely to travel far. Patients who were Asian/Pacific Islander lived the closest to a high-quality hospital. Conclusions: Among California women diagnosed with OC, living closer to a high-quality center was associated with receiving adherent care. Non-Hispanic black women were less likely to receive adherent care, and women with lower SES lived farthest from high-quality hospitals. Geographic location in California is an independent predictor of adherence to NCCN Guidelines for OC.
STEM-20. RADIO-SENSITIZING GLIOBLASTOMA CANCER STEM CELLS BY INHIBITION OF FACT
Authors: Miranda Montgomery, Abigail Zalenski, Amanda Deighen, Sherry Mortach, Treg Grubb, Monica Venere
Journal: Neuro-Oncology (2019)

Abstract Glioblastoma (GBM) has a particularly high rate of recurrence with a 5-year overall survival rate of approximately 5%. This is in part due to a sub-population of cancer stem cells (CSC), which are both radioresistant and chemotherapeutically resistant to conventional treatments. Here we investigated CBL0137, a small molecule form of curaxin, in combination with radiotherapy as a means to radiosensitize CSCs. CBL0137 sequesters FACT (facilitates chromatin transcription) complex to chromatin, which leads to activation of p53 and inhibition of NF-κB. This sequestering of FACT results in cytotoxicity especially within tumor cells and prevents FACT from performing its primary role as a histone chaperone, as well as inhibits its part in the DNA damage response pathway. We show that when combined with radiotherapy, CBL0137 administration limited the ability of CSCs to identify and repair damaged DNA. CSCs treated in vitro with CBL0137 and irradiation showed an increased inhibition of cancer cell growth and decreased viability compared to irradiation or drug alone. Combination therapy also showed more DNA damage in the CSCs than with either agent alone. Based on our in vitro evidence for the efficacy of combination therapy to target CSCs, we moved forward to test the treatment in vivo. Using a subcutaneous model, we show that the amount of CD133+ cells (a marker for GMB CSCs) was reduced in irradiation plus CBL0137 compared to either treatment alone. Survival studies demonstrated that irradiation plus CBL0137 compared to irradiation alone or CBL0137 alone increase lifespan. Here we show the ability of CBL0137, in combination with irradiation, to target patient GBM CSCs both in vitro and in vivo. This work establishes a new treatment paradigm for GBM that inclusively targets CSCs and may ultimately reduce tumor recurrence.
A Pilot Trial of Adriamycin, Pembrolizumab, Vinblastine and Dacarbazine (APVD) for Patients with Untreated Classical Hodgkin Lymphoma
Authors: Ryan C. Lynch, Chaitra S. Ujjani, Edus H. Warren, David M. Kurtz, Hilary Coye, Jacquelin Vandermeer, Hongyan Du, Adam Greenbaum, Ajay K. Gopal
Journal: Blood (2019)
Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common
Authors: Stephen Booth, Hannah Plaschkes, Amy A Kirkwood, Adam Gibb, Patrick Horgan, Joanna M Oladipo, Joseph Andrew Browning, Usman Khan, John Willan, Julia Wolf, Arief Gunawan, Paul A Fields, Kim Linton, Claire Higham, Graham P. Collins, Jaimal Kothari, Catherine Hildyard, Toby A. Eyre
Journal: Blood (2019)
Tissue-Specific Macrophage Responses to Remote Injury Impact the Outcome of Subsequent Local Immune Challenge
Authors: Friedrich Felix Hoyer, Kamila Naxerova, Maximilian J. Schloss, Maarten Hulsmans, Anil V. Nair, Partha Dutta, David M. Calcagno, Fanny Herisson, Atsushi Anzai, Yuan Sun, Gregory Wojtkiewicz, David Rohde, Vanessa Frodermann, Katrien Vandoorne, Gabriel Courties, Yoshiko Iwamoto, Christopher S. Garris, David L. Williams, Sylvie Breton, Dennis Brown, Michael Whalen, Peter Libby, Mikael J. Pittet, Kevin R. King, Ralph Weissleder, Filip K. Swirski, Matthias Nahrendorf
Journal: Immunity (2019)
THE REPORT ON MEDICAL EDUCATION.
Authors: W F Snow
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Immune Phenotyping of Cytotoxic T-Cells Reveals a Novel Population of TIM3 Expressing Cells That Lack PD1 and Are Associated with Good Outcomes in Marginal Zone Lymphoma
Authors: Theodora Anagnostou, Zhi-Zhang Yang, Hyojin Kim, Shahrzad Jalali, Jose C Villasboas, Hongyan Wu, Tammy Price-Troska, Anne J Novak, Stephen M Ansell
Journal: Blood (2019)
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel
Authors: Charalambos Andreadis, Constantine S. Tam, Peter Borchmann, Ulrich Jaeger, Joseph P. McGuirk, Harald Holte, Edmund K. Waller, Samantha Jaglowski, Michael R. Bishop, Stephen Ronan Foley, Jason R. Westin, Isabelle Fleury, P Joy Ho, Stephan Mielke, Takanori Teshima, Gilles A. Salles, Stephen J Schuster, Veronika Bachanova, Richard T. Maziarz, Koen Van Besien, Koji Izutsu, John M. Magenau, Nina D. Wagner-Johnston, Koji Kato, Paolo Corradini, Ranjan Tiwari, Rakesh Awasthi, Tomasz Lawniczek, Lamis K. Eldjerou, Marie Jose Kersten
Journal: Blood (2019)
Estimated Glomerular Filtration Rate Is an Independent Predictor of Outcome in High-Risk Myelodysplastic Syndrome (MDS) and Low Blast Count Acute Myeloid Leukaemia (AML) Patients Treated with Azacytidine (AZA). a Retrospective Study from the MDS Registry of the Hellenic MDS Study Group
Authors: Sotirios Papageorgiou, Vasileios Papadopoulos, Papoutselis Menelaos, Anthi Bouhla, Argiris Symeonidis, Athanasios Galanopoulos, Nora-Athina Viniou, Eleftheria Hatzimichael, Dimitrios Gogos, Panagiotis Zikos, Theodoros P. Vassilakopoulos, Alexandra Kourakli, Panagiota Giannoulia, George Vrachiolias, Aikaterini Megalakaki, Panagiotis T Diamantopoulos, Elias Poulakidas, Anna Vardi, Achilles Anagnostopoulos, Despoina Mparmparousi, Maria Papaioannou, Eleni Mpouronikou, Helen A. Papadaki, Maria Dimou, Panayiotis Panayiotidis, Vassiliki Pappa, Ioannis Kotsianidis
Journal: Blood (2019)
Pharmacokinetic and Pharmacodynamic Effects of PEG-Asparaginase in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia: Results from a Single Agent Window Study.
Authors: Inge M. Appel, Karin M. Kazemier, Anjo J.P. Veerman, Elisabeth van Wering, Monique L. Den Boer, Rob Pieters
Journal: Blood (2007)
Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results
Authors: Kerri Beckmann, Danielle Crawley, Tobias Nordström, Markus Aly, Henrik Olsson, Anna Lantz, Noor Binti Abd Jalal, Hans Garmo, Jan Adolfsson, Martin Eklund, Mieke Van Hemelrijck
Journal: JAMA Network Open (2019)

<h3>Importance</h3> Diabetic men appear to have a lower risk of prostate cancer. Whether antidiabetic medications are protective or potentially mask prostate cancer by lowering prostate-specific antigen (PSA) levels is unclear. <h3>Objective</h3> To examine the associations of antidiabetic medication use with (1) PSA levels, (2) frequency of PSA testing, (3) receipt of biopsy following elevated PSA results, and (4) prostate cancer detection at biopsy. <h3>Design, Setting, and Participants</h3> Population-based cohort study using data from the Stockholm PSA and Biopsy Register. Participants were all prostate cancer–free men aged 40 to 79 years residing in Stockholm County, Sweden, between January 1, 2006, and December 31, 2015. Data were analyzed from November 2018 to March 2019. <h3>Exposures</h3> One or more prescription for metformin, sulfonylurea, or insulin, as recorded in Sweden's National Prescribed Drug Register. <h3>Main Outcomes and Measures</h3> Levels of PSA following first exposure to antidiabetic medications were assessed using multivariable linear regression. Frequency of PSA testing was assessed via multivariable Poisson regression. Biopsy following elevated PSA (≥3.0 ng/mL) and prostate cancer detection at biopsy were assessed via multivariable logistic regression. <h3>Results</h3> The cohort of 564 666 men (median [range] age, 65 [40-79] years) consisted of 4583 men initially exposed to metformin, 1104 exposed to sulfonylurea, and 978 exposed to insulin who were age matched with unexposed men (1:5). Exposed men had lower median (interquartile range) PSA levels before starting antidiabetic medications compared with unexposed men (1.2 [0.7-2.5] vs 1.6 [0.8-3.2] ng/mL). After accounting for baseline differences, PSA levels did not vary from those of unexposed men following exposure to antidiabetic medications. Frequency of PSA testing was higher for those receiving metformin (rate ratio, 1.07; 95% CI, 1.06-1.09) and sulfonylurea (rate ratio, 1.06; 95% CI, 1.03-1.08) but was lower for those receiving insulin (rate ratio, 0.79; 95% CI, 0.77- 0.81). Likelihood of biopsy after elevated PSA was lower among men receiving metformin (odds ratio, 0.87; 95% CI, 0.80-0.96) and insulin (odds ratio, 0.83; 95% CI, 0.74-0.93). There were no differences in prostate cancer detection at biopsy, regardless of PSA levels that triggered the biopsy. <h3>Conclusions and Relevance</h3> This study's findings do not support the hypothesis that the inverse association between diabetes and prostate cancer is mediated through antidiabetic medications lowering PSA levels to mask prostate cancer. They do suggest potential detection bias due to fewer biopsies among men receiving antidiabetic medications, which may explain the lower prostate cancer risk in men with diabetes.
Effectiveness and Survival of 4 Courses of Chemotheray in 321 Children with Acute Myeloid Leukemia in China: A Multicenter, Nonrandomized Clinical Study
Authors: Zheng Yong Zhi, Jian Li, Xiaoqin Feng, Mincui Zheng, Chunfu Li, Honggui Xu, Yingyi He, Huirong Mai, Xiangling He, Lihua Yang, Hong Wen
Journal: Blood (2019)
<i>Mycobacterium tuberculosis</i>: concentrate resources on recent infections
Authors: Paul D van Helden, Eileen G Hoal
Journal: BMJ (2019)

Behr and colleagues1 conclude that tuberculosis (TB) has a much shorter incubation time than previously thought. This is supported by a considerable body of circumstantial and direct evidence—for example, the multiple papers that show that recent transmission (RT) is high, even in developed countries with low incidence. Estimates ranging from 80-96% for RT data fit well with the estimates of …
Type I Interferon Response Identified through Phenotypic and Transcriptional Profiling of Circulating Immune Cells during Idiopathic Multicentric Castleman Disease Flare
Authors: Ruth-Anne Langan, Alberto Japp, Michael Gonzalez, Rozena Rasheed, Sheila K Pierson, Charlly Kao, Hakon Hakonarson, Frits van Rhee, Michael Betts, Taku Kambayashi, David C Fajgenbaum
Journal: Blood (2019)
Phase II Multicenter, Not Comparative, Study of Multiple Doses of NEPA (netupitant + palonosetron) in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in Non-Hodgkin Lymphoma Patients Eligible for Autologous Hematopoietic Stem Cell Transplantation Receiving Multiple Days / High Dose Chemotherapy Regimens
Authors: Nicola Di Renzo, Maurizio Musso, Rosanna Scimè, Giuseppe Milone, Tommasina Perrone, Clara De Risi, Domenico Pastore, Attilio Guarini, Andrea Mengarelli, Fabio Benedetti, Patrizio Mazza, Vera Capria, Patrizia Chiusolo, Luca Cupelli, Vincenzo Federico, Valentina Bozzoli, Anna Rita Messa, Giorgina Specchia
Journal: Blood (2019)
Innate Immune Signaling Suppresses Acute Leukemia By Modifying MYC Oncogenic Activity
Authors: Tomoya Muto, Maria Guillamot, Jing Fang, Luna Zea Redondo, Kwangmin Choi, Yixiao Gong, Callum S Walker, Kathleen Hueneman, Lyndsey C Bolanos, Laura Barreyro, Lynn Lee, Kenneth D Greis, Alireza Khodadadi-Jamayran, Amaia Lujambio, Scott W. Lowe, Iannis Aifantis, Daniel T. Starczynowski
Journal: Blood (2019)
Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation
Authors: Yannick LE Bris, Thierry Guillaume, Camille Debord, Pierre Peterlin, Soraya Wuilleme, Céline Bressollette, Amandine Le Bourgeois, Alice Garnier, Aurélie Fantou, Marie Audrain, Audrey Ménard, Nelly Robillard, Marion Eveillard, Steven Le Gouill, Berthe Marie Imbert, Marie C Bene, Patrice Chevallier
Journal: Blood (2019)
Annals Story Slam - Leaving Too Early, Arriving Too Late
Authors: Lorraine Lipscombe
Journal: Annals of Internal Medicine (2019)

Web Exclusives5 November 2019Annals Story Slam - Leaving Too Early, Arriving Too LateFREELorraine Lipscombe, MD, MScLorraine Lipscombe, MD, MScSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W19-0027 SectionsAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Video. Annals Story Slam - Leaving Too Early, Arriving Too Late "Leaving Too Early, Arriving Too Late," by Lorraine Lipscombe, MD, MSc (Duration 6:09)Building on the popular Annals feature “On Being a Doctor,” storytellers share stories about the experience of doctoring on video.For more videos from and information on Annals Story Slam, visit go.annals.org/StorySlam. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 5 November 2019Volume 171, Issue 9Page: SS1 ePublished: 5 November 2019 Issue Published: 5 November 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
SURG-03. THERAPEUTIC VALUE OF SURGICAL RESECTION OF BRAIN METASTASES: A RETROSPECTIVE ANALYSIS OF 147 CASES
Authors: Yonggao Mou, Hao Duan, Zhenqiang He, Chengcheng Guo, Xiaobing Jiang
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE Brain metastases are the most common malignant tumors of the central nervous system. In patients with brain metastases with surgical indications, total surgical resection is the most effective treatment for prolonging patient survival and relieving neurological symptoms. In this study, the clinical data of 147 patients in a single group underwent microsurgery of brain metastases were retrospectively analyzed to investigate the therapeutic value of microsurgery in patients with brain metastases. METHODS From January 2000 to December 2017, patients who underwent microsurgical removal of brain metastases from the Department of Neurosurgery in Sun Yat-sen University Cancer Center were retrospectively analyzed. The clinical and pathological features and prognosis of the patients were collected and analyzed. The characteristics of brain metastases were analyzed through surgical recording and videos. RESULTS A total of 147 patients were enrolled, including 86 males and 61 females. The average age was 54.4 years, of which 125 were younger than 65 years old. 137 people with KPS ≥ 70. 95.9% (141 patients) had an RPA grade of I-II, of which 51 (34.7%) were RPA class I and 90 (61.2%) were RPA class II. 90.5% (133 patients) were single brain metastases. 71.5% (105 cases) of patients with metastases are located in the cerebral area. The distribution of primary lesions suggested that the lung cancer was the most, reaching 62.6%; followed by breast source (10.9%). The surgical video analysis suggest that most brain metastatic lesions have obvious supplying vessels, relatively clear boundaries with a pseudo-capsule structure. The 5-year OS of all patients reached 15% with a median survival of 42.3 months. CONCLUSION The brain metastases have clear blood supplying vessels and relatively clear boundaries that favors gross total resection. Surgical treatment is associated with better prognosis in patients with brain metastases.